Trials / Unknown
UnknownNCT04479553
Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30,000 (estimated)
- Sponsor
- Zhong Wang · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This registry aims to monitor the safety of Qizhi Tongluo Capsules and to identify the potential risk factors for its adverse drug reactions.
Conditions
- Safety Surveillance
- Adverse Drug Events
- Adverse Drug Reactions
- Severe Adverse Events
- Severe Adverse Reactions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Qizhi Tongluo Capsules | Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001). |
Timeline
- Start date
- 2020-08-17
- Primary completion
- 2023-09-01
- Completion
- 2023-12-01
- First posted
- 2020-07-21
- Last updated
- 2022-11-15
Locations
14 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04479553. Inclusion in this directory is not an endorsement.